Chief Executive Officer
Dr. Gaddipati has more than 20 years of experience in the oncology domain. She is a clinical oncologist and geneticist with basic science and clinical trial expertise. She holds a master’s degree from the Wharton Business School and has also served at the US FDA and National Cancer Institute. Dr Gaddipati’s expertise spans clinical, scientific, regulatory and commercialization realms of the cancer product development lifecycle. Over the past 2 decades she has treated patients with complex oncologic disorders and genetic conditions. She served as a visiting scientist in the division of molecular oncogenesis, Wistar Research Institute in Philadelphia. She gained valuable insight about the regulatory requirements for marketing approval of drugs in the division of oncology drugs products, US FDA. She brings a nuanced comprehension about the inherent challenges involved in integrating diverse expertise along the value chain. Her belief is that by addressing the inefficiencies along the translational spectrum exponential greater advancement can be achieved in cancer care.
Chief Scientific Officer
Dr. Kulkarni’s core scientific expertise includes cancer biology, molecular carcinogenesis, and genomics. He has held several senior management positions and has been instrumental in setting up several high-value collaborations with clinical and research oncologists. As an effective member of senior executive team he also brings with him experience in strategic leadership, developing a corporate culture, establishing new initiatives, and knowledge across most functional areas of startups.
Chief Innovation Officer
Dr. Medicetty is a Consultant in Cleveland Clinic, Ohio and has a great vision to create impactful platforms that bring together right people to drive the future of science medicine. He is a biotech entrepreneur and his background include a unique blend of executive management, business development and scientific expertise.
Senior Business Advisor
Mr. Stambaugh is known for his visionary leadership in innovation and high-growth businesses. During his more than 40-year career Mr. Stambaugh’s visionary leader has built successful management teams around his ability to awaken the leader within his associates to have them achieve extraordinary results. Mr. Stambaugh has raised over $500 million of capital in private and public financing. He has taken a company public in both the U.S. and Europe. He has completed several strategic partnerships with Fortune 100 and other companies. As the founding principal at Apercu Partners, he currently serves as Chairman of selected entrepreneurial companies and mentor/coach to CEO’s and boards.
Chief Technology Officer
Dr. Doraisamy has expertise in the areas of nano-bio technologies, biomarker detection, microfluidics and next generation sequencing technologies for healthcare and bio-defense. He has successfully led collaborations between various stakeholders such as biotech industry, university researchers, clinical and government laboratories, US government funding agencies, private investors and customers, enabling R&D, product development and commercialization.
Director, Platform Development
Mr. Kodali has over 23 years of IT experience in Life Sciences / Supply Chain Domain with strong delivery background with an excellent blend of technical and business skills. Experienced in setting strategy and overseeing the operations of various departments, developing and maintaining customer and partner relationships, building high-performing global application teams and ecosystems.
Brett is a commercial banker in San Diego. He has expertise in the area of partnering with Healthcare organizations to acquire financing. Throughout his career, he has successfully funded over $200 million, ranging from initial seed/start-up financing, to mature traditional bank financing.